NASDAQ$GYRE
Gyre Therapeutics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Catalyst Biosciences reported results for the second quarter of 2021 and provided a corporate update.
Catalyst Biosciences reported a net loss of $19.9 million for the second quarter of 2021. The company is advancing its complement and hemostasis programs, with key milestones including the initiation of the ConFIrm study for CFI deficiency and progress in the Crimson 1 Phase 3 registrational study of MarzAA.
- Advanced the development of CB 4332, an SQ enhanced CFI development candidate, and screened the first patient in the ConFIrm study for CFI deficiency.
- Disclosed new proteases from ProTUNE™ and ImmunoTUNE™ platforms targeting specific disorders of the complement or inflammatory pathways.
- Continued progress in the Crimson 1 Phase 3 registrational study of MarzAA in hemophilia A or B with inhibitors and in the Phase 1/2 trial in other rare bleeding disorders.
- The FDA granted Fast Track Designation for MarzAA for treatment of episodic bleeding in subjects with Factor FVII deficiency in June 2021.
Headline financials
Revenue & EPS history
Gyre Therapeutics · Revenue · Quarterly
$1.13M
Revenue by segment
Gyre Therapeutics · $1.13M total across 1 segment · Q2 2021
- License & Collaboration$1.13M—100.0%
Forward guidance
Catalyst Biosciences expects to advance its CB 2782-PEG program, provide additional preclinical data for the C4b degrader program, submit an IND and initiate a global clinical trial of CB 4332, announce development candidates in lead discovery programs, and present PK and biomarker data for CB 4332. The company also plans to continue enrolling the Crimson 1 Phase 3 registrational and Phase 1/2 trials, submit the first Crimson 1 report to the DSMB, and present PK data from the Phase 1/2 trial.
Tailwinds
- Advance CB 2782-PEG, the C3 degrader for the potential treatment of dry AMD in collaboration with Biogen towards the clinic
- Provide additional preclinical data supporting continued development of the C4b degrader program and other complement assets
- Submit an IND and initiate global clinical trial of CB 4332
- Announce development candidates in lead discovery programs
- Present PK and biomarker data for CB 4332
Headwinds
- Trials and studies may be delayed as a result of COVID-19, competitive products and other factors
- Trials may not have satisfactory outcomes
- The ConFIrm and ConFIdence trials will not validate the potential market for CB 4332
- Catalyst may elect to terminate or postpone ongoing development programs, including development of MarzAA or any of the Company’s complement assets
- The Company will need to raise additional capital, which may not be available on favorable terms if at all
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-0.7%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+8.5%
Avg return
30 days after
49%
23 / 47 earnings
Positive
+11.6%
Q3 2018
Best reaction
-43.2%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.8% | +2.8% | -11.2% | |
| Q4 2025 | +2.0% | -10.2% | -5.4% | |
| Q3 2025 | -1.6% | +13.6% | +8.7% | |
| Q1 2025 | +0.5% | +9.6% | -11.3% | |
| Q3 2024 | -13.6% | -21.2% | -39.8% | |
| Q2 2024 | -6.5% | +2.1% | +28.7% | |
| Q1 2024 | -5.5% | +0.5% | -29.3% | |
| Q4 2023 | +8.3% | +8.0% | +0.9% | |
| Q3 2023 | +0.0% | -15.3% | +144.2% | |
| Q2 2023 | +8.8% | +58.8% | +50.0% | |
| Q1 2023 | +5.0% | +5.0% | +5.0% | |
| Q4 2022 | +5.0% | +5.0% | +5.0% | |
| Q3 2022 | -1.8% | +0.0% | -12.5% | |
| Q2 2022 | -1.6% | +3.6% | +2.1% | |
| Q1 2022 | -24.5% | -26.5% | +173.5% | |
| Q4 2021 | +0.0% | -3.0% | -27.3% | |
| Q3 2021 | -43.2% | -51.0% | -62.9% | |
| Q2 2021 | +7.4% | +3.7% | +10.3% | |
| Q1 2021 | -2.4% | -5.4% | -9.5% | |
| Q3 2020 | +4.5% | +7.4% | +11.3% | |
| Q2 2020 | -0.6% | -2.0% | -13.5% | |
| Q1 2020 | +7.2% | -2.7% | +21.9% | |
| Q3 2019 | -3.1% | -6.1% | -8.7% | |
| Q2 2019 | +6.7% | -3.2% | -22.1% | |
| Q1 2019 | -5.3% | +2.7% | -9.2% | |
| Q3 2018 | +11.6% | +24.7% | +20.0% | |
| Q2 2018 | +6.6% | +6.6% | +11.9% | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | +1.2% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2014 | +3.7% | — | — | |
| Q4 2013 | -0.8% | — | — | |
| Q3 2013 | -5.4% | — | — | |
| Q2 2013 | -3.6% | — | — | |
| Q1 2013 | +0.5% | — | — | |
| Q4 2012 | -0.5% | — | — | |
| Q3 2012 | +0.7% | — | — | |
| Q2 2012 | -0.9% | — | — | |
| Q1 2011 | -2.7% | — | — | |
| Q1 2012 | +0.4% | — | — | |
| Q4 2011 | +0.1% | — | — | |
| Q4 2009 | +0.1% | — | — | |
| Q3 2010 | +3.9% | — | — | |
| Q3 2011 | +3.9% | — | — | |
| Q2 2010 | -1.4% | — | — | |
| Q2 2011 | -1.4% | — | — | |
| Q4 2010 | -1.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro